Literature DB >> 28685324

Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children.

Sulaiman M Al-Mayouf1,2, Nora AlMutiari3, Mohammed Muzaffer4, Rawiah Shehata5, Adel Al-Wahadneh6, Reem Abdwani7, Safia Al-Abrawi8, Mohammed Abu-Shukair6, Zeyad El-Habahbeh6, Abdullah Alsonbul3.   

Abstract

This study describes the disease characteristics and outcome of Arab children with juvenile dermatomyositis (JDM) and compares the findings with other ethnicities. We retrospectively reviewed the hospital registries of the participating hospitals for children with JDM seen between 1990 and 2016 in three Arab countries. All patients fulfilled Bohan and Peter criteria for JDM, diagnosed before 14 years of age and were of Arab ethnicity. Clinical and laboratory features as well as the long-term outcomes including accrual disease damage were collected at the last follow-up visit. A total of 92 JDM patients (58 girls) were included. Mean age at the onset was 6 ± 3 years, with a mean follow-up duration of 5 ± 4.4 years. Forty-three patients (46.7%) had polycyclic disease course, 34 (36.9%) had a monocyclic course, while 15 (16.3%) had a continuous progressive course. Forty-five patients (48.9%) had arthritis, 14 (15.2%) patients had an upper airway and dysphagia, and 10 patients (10.9%) had lung involvement. Eight patients (8.7%) were admitted to the intensive care unit (ICU), 4 of them required mechanical ventilation. Methotrexate had been the most frequently used immunosuppressive drug (86%) and rituximab was used in eight patients. Additionally, 31 patients received IVIG. Most of the patients achieved a complete clinical response, but 16 ended up with permanent skin changes and 12 had a residual muscle weakness. Twenty-seven patients developed calcinosis. There were two deaths due to infection during the follow-up period. We report the largest phenotypic data on Arab children with JDM. Our patients have similar characteristics to previously described cohorts. Majority of the patients remained with inactive disease.

Entities:  

Keywords:  Arab; Calcinosis; Disease damage; Juvenile dermatomyositis; Outcome

Mesh:

Year:  2017        PMID: 28685324     DOI: 10.1007/s00296-017-3770-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.

Authors:  A Marco Puche; I Calvo Penades; B Lopez Montesinos
Journal:  Clin Exp Rheumatol       Date:  2010 Jan-Feb       Impact factor: 4.473

2.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.

Authors:  L J McCann; A D Juggins; S M Maillard; L R Wedderburn; J E Davidson; K J Murray; C A Pilkington
Journal:  Rheumatology (Oxford)       Date:  2006-03-27       Impact factor: 7.580

3.  Juvenile dermatomyositis: clinical profile and disease course in 25 patients.

Authors:  R Shehata; S al-Mayouf; A al-Dalaan; A al-Mazaid; S al-Balaa; S Bahabri
Journal:  Clin Exp Rheumatol       Date:  1999 Jan-Feb       Impact factor: 4.473

4.  Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate.

Authors:  S Al-Mayouf; A Al-Mazyed; S Bahabri
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

5.  Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.

Authors:  S M Al-Mayouf; R M Laxer; R Schneider; E D Silverman; B M Feldman
Journal:  J Rheumatol       Date:  2000-10       Impact factor: 4.666

6.  Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset.

Authors:  Helga Sanner; Jan-Tore Gran; Ivar Sjaastad; Berit Flatø
Journal:  Rheumatology (Oxford)       Date:  2009-09-23       Impact factor: 7.580

Review 7.  Recent advances in juvenile idiopathic inflammatory myopathies.

Authors:  Floranne C Ernste; Ann M Reed
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

8.  Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.

Authors:  Isha Saini; Mani Kalaivani; Sushil Kumar Kabra
Journal:  Rheumatol Int       Date:  2016-03-23       Impact factor: 2.631

9.  Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis.

Authors:  Dinara Guseinova; Alessandro Consolaro; Lucia Trail; Cristina Ferrari; Angela Pistorio; Nicolino Ruperto; Antonella Buoncompagni; Clarissa Pilkington; Susan Maillard; Sheila K Oliveira; Flavio Sztajnbok; Ruben Cuttica; Fabrizia Corona; Maria Martha Katsicas; Ricardo Russo; Virginia Ferriani; Ruben Burgos-Vargas; Eunice Solis-Vallejo; Marcia Bandeira; Vicente Baca; Claudia Saad-Magalhaes; Clovis A Silva; Roberto Barcellona; Luciana Breda; Rolando Cimaz; Romina Gallizzi; Rosaria Garozzo; Silvana Martino; Antonella Meini; Achille Stabile; Alberto Martini; Angelo Ravelli
Journal:  Clin Exp Rheumatol       Date:  2011-02-23       Impact factor: 4.473

10.  Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.

Authors:  Anjali Patwardhan; Robert Rennebohm; Igor Dvorchik; Charles H Spencer
Journal:  Pediatr Rheumatol Online J       Date:  2012-09-20       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.